文献速递骨质疏松与代谢性骨病

慢性肾脏病患者骨质疏松症的管理

Management of osteoporosis in patients with chronic kidney disease.
PubMed 文献 · Osteoporos Int · 2022-06-24

慢性肾脏病患者骨折率升高4至5倍,且随肾功能恶化而增加。骨强度受损源于骨量和/或骨质量下降,骨折对生活质量和死亡率有不良影响。本文聚焦慢性肾脏病-矿物质和骨异常(CKD-MBD)与骨质疏松的最新管理,强调骨丢失机制决定药物治疗选择,DXA和QCT评估骨量,TBS、高分辨率骨影像、骨活检和骨转换标志物可指导骨丢失机制判断。

要点

  • 慢性肾脏病患者骨折率升高4至5倍,且随肾功能恶化而增加。
  • 骨丢失机制主要决定药物治疗选择,骨质量评估可指导机制判断。
  • 抗骨吸收治疗可改善骨密度和降低骨折风险,但晚期慢性肾脏病患者的安全性和疗效存在不确定性。

核心结论

  • 慢性肾脏病恶化骨质量和骨量,骨丢失机制主要决定药物治疗选择。
  • DXA和QCT提供骨量信息,TBS、高分辨率骨影像、侵入性骨活检和骨转换标志物可指导骨丢失机制判断。

研究设计与样本

  • 本文为综述,聚焦慢性肾脏病患者CKD-MBD和骨质疏松的最新管理。

主要发现

  • 慢性肾脏病患者骨折率升高4至5倍,骨折发生率随肾功能恶化而增加。
  • 骨丢失和骨折的发病机制复杂且多因素,肾性骨营养不良、尿毒症环境、药物和导致肾衰竭的系统性疾病均参与骨损伤。
  • 抗骨吸收治疗可有效改善骨密度和降低骨折风险,但在晚期慢性肾脏病患者中安全性和疗效存在不确定性。
  • 鉴于晚期慢性肾脏病患者低骨转换普遍,骨合成代谢药物可能是有前景的。
  • 甲状旁腺切除术应被视为难治性肾性甲状旁腺功能亢进症的最后手段。

关键数值与推荐

  • 骨量和骨质量可通过双能X线吸收测定法(DXA)或定量CT(QCT)评估。
  • 骨质量可通过非侵入性方法如骨小梁评分(TBS)、高分辨率骨影像方法和侵入性骨活检评估。
  • 骨转换标志物可反映骨重建,但部分标志物被肾脏潴留。

临床怎么用

  • 控制CKD-MBD的实验室异常至关重要。
  • 抗骨吸收治疗可改善骨密度和降低骨折风险,但晚期慢性肾脏病患者的安全性和疗效存在不确定性。
  • 骨合成代谢药物在晚期慢性肾脏病患者中可能是有前景的。
  • 甲状旁腺切除术应被视为难治性肾性甲状旁腺功能亢进症的最后手段。
  • 慢性肾脏病患者骨质疏松管理存在广泛且不可接受的差距。

局限性

  • 慢性肾脏病患者骨评估的最佳诊断方法尚无共识。
  • 抗骨吸收治疗在晚期慢性肾脏病患者中的安全性和疗效存在不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with CKD have a 4-fivefold higher rate of fractures. The incidence of fractures increases with deterioration of kidney function. The process of skeletal changes in CKD patients is characterized by compromised bone strength because of deterioration of bone quantity and/or quality. The fractures lead to a deleterious effect on the quality of life and higher mortality in patients with CKD. The pathogenesis of bone loss and fracture is complex and multi-factorial. Renal osteodystrophy, uremic milieu, drugs, and systemic diseases that lead to renal failure all contribute to bone damage in CKD patients. There is no consensus on the optimal diagnostic method of compromised bone assessment in patients with CKD. Bone quantity and mass can be assessed by dual-energy x-ray absorptiometry (DXA) or quantitative computed tomography (QCT). Bone quality on the other side can be assessed by non-invasive methods such as trabecular bone score (TBS), high-resolution bone imaging methods, and invasive bone biopsy. Bone turnover markers can reflect bone remodeling, but some of them are retained by kidneys. Understanding the mechanism of bone loss is pivotal in preventing fracture in patients with CKD. Several non-pharmacological and therapeutic interventions have been reported to improve bone health. Controlling laboratory abnormalities of CKD-MBD is crucial. Anti-resorptive therapies are effective in improving BMD and reducing fracture risk, but there are uncertainties about safety and efficacy especially in advanced CKD patients. Accepting the prevalent of low bone turnover in patients with advanced CKD, the osteo-anabolics are possibly promising. Parathyroidectomy should be considered a last resort for intractable cases of renal hyperparathyroidism. There is a wide unacceptable gap in osteoporosis management in patients with CKD. This article is focusing on the updated management of CKD-MBD and osteoporosis in CKD patients. Chronic kidney disease deteriorates bone quality and quantity. The mechanism of bone loss mainly determines pharmacological treatment. DXA and QCT provide information about bone quantity, but assessing bone quality, by TBS, high-resolution bone imaging, invasive bone biopsy, and bone turnover markers, can guide us about the mechanism of bone loss.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Abdalbary M, Sobh M, Elnagar S, et al. Management of osteoporosis in patients with chronic kidney disease. Osteoporos Int. 2022. PMID: 35748896. doi:10.1007/s00198-022-06462-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。